tafenoquine has been researched along with Parasitemia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Abd-Rahman, AN; Barber, BE; Birrell, GW; Edstein, MD; Leelasena, I; Llewellyn, S; Marquart, L; McCarthy, JS; Moehrle, JJ; Potter, AJ; Sahai, N; Shanks, GD; Webster, R; Wesche, D | 1 |
| Fernando, D; Rajapakse, S; Rodrigo, C | 1 |
| Berman, J; Dobbin, C; Dow, GS; Marquart, L; McCarthy, JS; Read, LT; Reid, M; Smith, B; West, L | 1 |
| Abdissa, A; Abebe, C; Angus, B; Batista Pereira, D; Beck, HP; Brand, F; Breton, JJ; Brito, MAM; Buathong, N; Casapía, M; Chuquiyauri, R; Clover, DD; Costa, MRF; Diro, E; Duparc, S; Espino, FEJ; Fletcher, K; Getie, S; Green, JA; Hardaker, E; Jones, SW; Kellam, LM; Kleim, JP; Koh, GCKW; Krudsood, S; Lacerda, MVG; Llanos-Cuentas, A; Lon, C; Mia, RZ; Mohamed, K; Mohammed, R; Monteiro, WM; Noedl, H; Rousell, VM; Saunders, DL; Tada, MS; Ugwuegbulam, CO; Val, F; Wubie, KM; Yilma, D; Zeynudin, A | 1 |
| Angus, B; Aruachan, S; Bancone, G; Breton, JJ; Brito, MAM; Casapía, M; Chu, CS; Chuquiyauri, R; Clover, DD; Costa, MRF; Craig, G; Duparc, S; Green, JA; Hardaker, E; Hien, TT; Jones, SW; Kendall, L; Koh, GCKW; Lacerda, MVG; Llanos-Cuentas, A; Mohamed, K; Monteiro, WM; Namaik-Larp, C; Nguyen, CH; Nosten, FH; Papwijitsil, R; Rousell, VM; Val, F; Vélez, ID; Villegas, MF; Wilches, VM | 1 |
| Mordue, DG; Wormser, GP | 1 |
| Berman, J; DiTusa, C; Gettayacamin, M; Im-erbsin, R; Kozar, MP; Ohrt, C; Pybus, B; Sousa, J; Tungtaeng, A | 1 |
| Dutta, GP; Puri, SK | 1 |
| Kitchener, S; Nasveld, P | 1 |
| Fleck, SL; Peters, W; Robinson, BL | 1 |
| Cooper, RD; Kyle, DE; Nuzum, EO; Obaldia, N; Rieckmann, KH; Rossan, RN; Shanks, GD | 1 |
1 review(s) available for tafenoquine and Parasitemia
| Article | Year |
|---|---|
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Drug Administration Schedule; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Parasitemia; Placebos; Primaquine; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention | 2020 |
3 trial(s) available for tafenoquine and Parasitemia
| Article | Year |
|---|---|
Blood Schizonticidal Activity and Safety of Tafenoquine When Administered as Chemoprophylaxis to Healthy, Nonimmune Participants Followed by Blood Stage Plasmodium falciparum Challenge: A Randomized, Double-blind, Placebo-controlled Phase 1b Study.
Topics: Adult; Aminoquinolines; Antimalarials; Chemoprevention; Double-Blind Method; Female; Healthy Volunteers; Humans; Malaria, Falciparum; Male; Parasitemia; Placebos; Plasmodium falciparum; Schizonts; Young Adult | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; Glucosephosphate Dehydrogenase; Hemoglobins; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Malaria, Vivax; Male; Parasitemia; Plasmodium vivax; Primaquine; Secondary Prevention | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Humans; Kaplan-Meier Estimate; Malaria, Vivax; Male; Parasitemia; Plasmodium vivax; Primaquine; Prospective Studies; Secondary Prevention | 2019 |
7 other study(ies) available for tafenoquine and Parasitemia
| Article | Year |
|---|---|
Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Australia; Healthy Volunteers; Humans; Malaria, Falciparum; Parasitemia; Plasmodium falciparum | 2023 |
Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?
Topics: Aminoquinolines; Animals; Babesia microti; Babesiosis; Female; Malaria; Mice; Mice, SCID; Parasitemia; Plasmodium | 2019 |
Causal prophylactic efficacy of primaquine, tafenoquine, and atovaquone-proguanil against Plasmodium cynomolgi in a rhesus monkey model.
Topics: Aminoquinolines; Animals; Antimalarials; Atovaquone; Disease Models, Animal; Drug Combinations; Macaca mulatta; Malaria; Parasitemia; Plasmodium cynomolgi; Primaquine; Proguanil | 2014 |
Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys.
Topics: Aminoquinolines; Animals; Antimalarials; Female; Macaca mulatta; Malaria; Male; Monkey Diseases; Parasitemia; Plasmodium cynomolgi; Primaquine | 2003 |
Treatment of acute vivax malaria with tafenoquine.
Topics: Acute Disease; Administration, Oral; Adult; Aminoquinolines; Antimalarials; Humans; Malaria, Vivax; Male; Parasitemia; Treatment Outcome | 2005 |
The chemotherapy of rodent malaria. LIV. Combinations of 'Fenozan B07' (Fenozan-50F), a difluorinated 3,3'-spirocyclopentane 1,2,4-trioxane, with other drugs against drug-sensitive and drug-resistant parasites.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Drug Antagonism; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Malaria; Mefloquine; Mice; Naphthyridines; Parasitemia; Phenanthrenes; Phenylpropionates; Plasmodium berghei; Plasmodium yoelii | 1997 |
WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys.
Topics: Aminoquinolines; Animals; Antimalarials; Aotus trivirgatus; Chloroquine; Drug Resistance; Drug Therapy, Combination; Malaria, Vivax; Parasitemia | 1997 |